Table 2.

Clinical characteristics of patients and details of CHC and RHC and HBO treatment

Sex	Age/Therapy	Age/End of Follow-up	Diagnosis	Treatment	HBO IndicationIndikation	End of Therapy	Time till Haematuria [m]	RTOG/Gray before HBOT	Admissions to Hospital	Number blood transfusions	Duration till HBO [m]	HBO Treatments	Follow Up [m]	Events/Follow-up	RTOG/Gray after HBO
M	68	70	PCA	adj	RC	08/2008	34	3	5	0	4	40	33	no relapse	0
M	82	86	PCA	prim	RC	07/2004	54	3	3	0	15	24	53	no relapse	0
M	73	81	PCA	HDR	RC	08/2002	11	4	4	2	33	24	100	1x haematuria 2007	3
W	71	83	CCA	adj	RC	07/1997	30	3	3	0	28	128	142	no relapse	0
M	80	86	PCA	prim	RC	07/1998	5	4	2	2	110	40	78	no relapse	0
M	71	76	PCA	adj	RC	01/1999	76	4	2	1	36	35	28	no relapse, †2010	0
W	86	90	UCA	adj	RC	01/1990	234	4	3	2	0	6	29	no relapse, †2012	0
M	80	83	PCA	adj	RC	01/2000	124	4	3	3	1	51	16	SRC 2010, †2012	4
M	65	72	PCA	adj	RC	03/2000	50	4	3	1	30	26	94	no relapse	0
M	61	63	PCA	sal	RC	02/2010	20	4	3	4	7	20	133	no relapse	0
M	22	33	RPSS	comb	RC/CC	01/1999	43	4	2	12	11	34	28	no relapse	0
M	73	78	PCA	sal	RC/RP	07/2007	14	3	2	2	1	48	68	no relapse	0
M	65	71	PCA	adj	RC/RP	07/2003	48	4	3	2	3	20	49	no relapse, †2011	0
W	49	56	LE	prim	CC	01/1974	362	3	4	0	40	40	86	1x haematuria 2008	3
M	39	49	WG	prim	CC	01/1993	120	4	3	1	4	17	136	no relapse	0

†=deceased.